Physician profile
Philip D Ehrlich
NPI 1497706550
$6,197.04
in general payments reported to CMS, 2019-2025
21 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $471 · 2021: $570 · 2022: $504 · 2023: $1,186 · 2024: $1,202 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713 · Entertainment: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.07 |
| Entertainment | $306.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,137.81 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Glaukos Corporation | $950.38 | 2019-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $393.82 | 2023-2025 | |
| Nova Eye, INC. | $306.75 | 2025 | |
| Aerie Pharmaceuticals, INC. | $220.07 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $192.84 | 2023-2024 | Miebo, Vyzulta |
| Kala Pharmaceuticals, INC. | $169.18 | 2020-2022 | |
| Allergan, INC. | $122.65 | 2020-2021 | |
| Rxsight INC | $121.25 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $97.88 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.95 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $91.30 | 2022-2025 | Cequa |
| Dompe US, INC. | $82.90 | 2019-2024 | Oxervate |
| Horizon Therapeutics Plc | $41.04 | 2023 | Tepezza |
| Iridex Corporation | $37.02 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $29.81 | 2020-2022 | |
| Biotissue Holdings INC. | $28.31 | 2025 | |
| Ivantis, INC | $27.02 | 2020-2021 | |
| Shire North American Group INC | $21.10 | 2019 | |
| Harrow Eye, LLC | $15.55 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.